SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2.
Aged
Aged, 80 and over
B-Lymphocytes
/ metabolism
Biomarkers, Tumor
Cell Line, Tumor
Disease Susceptibility
Female
Gene Expression Regulation, Leukemic
Gene Knockout Techniques
Humans
Immunoglobulin Heavy Chains
/ genetics
Killer Cells, Natural
/ immunology
Leukemia, Lymphocytic, Chronic, B-Cell
/ diagnosis
Male
Middle Aged
Models, Biological
Prohibitins
RNA, Small Interfering
/ genetics
Receptors, Antigen, B-Cell
/ metabolism
Repressor Proteins
/ metabolism
Signal Transduction
Signaling Lymphocytic Activation Molecule Family
/ metabolism
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
11
03
2020
accepted:
07
08
2020
revised:
30
07
2020
pubmed:
23
8
2020
medline:
1
5
2021
entrez:
23
8
2020
Statut:
ppublish
Résumé
We identified a subset of Chronic Lymphocytic Leukemia (CLL) patients with high Signaling Lymphocytic Activation Molecule Family (SLAMF) receptor-related signaling that showed an indolent clinical course. Since SLAMF receptors play a role in NK cell biology, we reasoned that these receptors may impact NK cell-mediated CLL immunity. Indeed, our experiments showed significantly decreased degranulation capacity of primary NK cells from CLL patients expressing low levels of SLAMF1 and SLAMF7. Since the SLAMF
Identifiants
pubmed: 32826957
doi: 10.1038/s41375-020-01025-z
pii: 10.1038/s41375-020-01025-z
pmc: PMC8024197
doi:
Substances chimiques
Biomarkers, Tumor
0
Immunoglobulin Heavy Chains
0
PHB2 protein, human
0
Prohibitins
0
RNA, Small Interfering
0
Receptors, Antigen, B-Cell
0
Repressor Proteins
0
Signaling Lymphocytic Activation Molecule Family
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1073-1086Références
Jeyakumar D, O’Brien S. B cell receptor inhibition as a target for CLL therapy. Best Pract Res Clin Haematol. 2016;29:2–14.
doi: 10.1016/j.beha.2016.08.004
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
doi: 10.1056/NEJMoa1215637
Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88.
doi: 10.1200/JCO.2012.42.7906
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–37.
doi: 10.1056/NEJMoa1509388
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517–28.
doi: 10.1056/NEJMoa1812836
Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, Barrientos J, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432–43.
doi: 10.1056/NEJMoa1817073
Ian Mockridge C, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood. 2007;109:4424–31.
doi: 10.1182/blood-2006-11-056648
Guarini A, Chiaretti S, Tavolaro S, Maggio R, Peragine N, Citarella F, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood. 2008;112:782–92.
doi: 10.1182/blood-2007-12-127688
Shanafelt TD, Wang V, Kay NE, Hanson CA, O’Brien SM, Barrientos JC, et al. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with Chronic Lymphocytic Leukemia (CLL): a trial of the ECOG-ACRIN cancer. Blood. 2018;132 (Suppl 1):LBA4.
Veillette A. SLAM-family receptors: immune regulators with or without SAP-family adaptors. Cold Spring Harb Perspect Biol. 2010;2:a002469.
doi: 10.1101/cshperspect.a002469
Shachar I, Barak A, Lewinsky H, Sever L, Radomir L. SLAMF receptors on normal and malignant B cells. Clin Immunol. 2019;204:23–30.
doi: 10.1016/j.clim.2018.10.020
Coma M, Tothova E, Guman T, Hajikova M, Giertlova M, Sarissky M. Altered expression pattern of SLAM family receptors on pathological B cells of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2017;58:1726–9.
doi: 10.1080/10428194.2016.1251593
Weber K, Bartsch U, Stocking C, Fehse B. A multicolor panel of novel lentiviral “gene ontology” (LeGO) vectors for functional gene analysis. Mol Ther. 2008;16:698–706.
doi: 10.1038/mt.2008.6
Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84–87.
doi: 10.1126/science.1247005
Yáñez-Muñoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med. 2006;12:348.
doi: 10.1038/nm1365
Cheong TC, Compagno M, Chiarle R. Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system. Nat Commun. 2016;7:10934.
doi: 10.1038/ncomms10934
Schepers E, Glorieux G, Dhondt A, Leybaert L, Vanholder R. Flow cytometric calcium flux assay: evaluation of cytoplasmic calcium kinetics in whole blood leukocytes. J Immunol Methods. 2009;348:74–82.
doi: 10.1016/j.jim.2009.07.002
Kim DI, Jensen SC, Noble KA, Kc B, Roux KH, Motamedchaboki K, et al. An improved smaller biotin ligase for BioID proximity labeling. Mol Biol Cell. 2016;27:1188–96.
doi: 10.1091/mbc.E15-12-0844
Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15–22.
Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. Springer; 2000. p. 350.
Machida K, Thompson CM, Dierck K, Jablonowski K, Kärkkäinen S, Liu B, et al. High-throughput phosphotyrosine profiling using SH2 domains. Mol Cell. 2007;26:899–915.
doi: 10.1016/j.molcel.2007.05.031
Schliffke S, Buhs S, Bolz S, Gerull H, von Wenserski L, Riecken K, et al. The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia. Blood. 2018;131:1755–8.
doi: 10.1182/blood-2017-06-788166
Detre C, Keszei M, Romero X, Tsokos GC, Terhorst C. SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions. Semin Immunopathol. 2010;32:157–71.
doi: 10.1007/s00281-009-0193-0
Wu N, Veillette A. SLAM family receptors in normal immunity and immune pathologies. Curr Opin Immunol. 2016;38:45–51.
doi: 10.1016/j.coi.2015.11.003
Baba Y, Kurosaki T. Role of calcium signaling in B cell activation and biology. Cham: Springer; 2015. p. 143–74.
Tangye SG, Weerdt BCMvd, Avery DT, Hodgkin PD. CD84 is up-regulated on a major population of human memory B cells and recruits the SH2 domain containing proteins SAP and EAT-2. Eur J Immunol. 2002;32:1640.
doi: 10.1002/1521-4141(200206)32:6<1640::AID-IMMU1640>3.0.CO;2-S
Veillette A. Immune regulation by SLAM family receptors and SAP-related adaptors. Nat Rev Immunol. 2006;6:56–66.
doi: 10.1038/nri1761
Roux KJ, Kim DI, Raida M, Burke B. A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells. J Cell Biol. 2012;196:801–10.
doi: 10.1083/jcb.201112098
Paris LL, Hu J, Galan J, Ong SS, Martin VA, Ma H, et al. Regulation of Syk by phosphorylation on serine in the linker insert. J Biol Chem. 2010;285:39844–54.
doi: 10.1074/jbc.M110.164509
Lucas CR, Cordero-Nieves HM, Erbe RS, McAlees JW, Bhatia S, Hodes RJ, et al. Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes. J Immunol. 2013;190:723–36.
doi: 10.4049/jimmunol.1201646
Terashima M, Kim KM, Adachi T, Nielsen PJ, Reth M, Kohler G, et al. The IgM antigen receptor of B lymphocytes is associated with prohibitin and a prohibitin-related protein. EMBO J. 1994;13:3782–92.
doi: 10.1002/j.1460-2075.1994.tb06689.x
Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9:495.
doi: 10.1038/ni1581
Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129:3419–27.
doi: 10.1182/blood-2017-02-765685
Bologna C, Buonincontri R, Serra S, Vaisitti T, Audrito V, Brusa D, et al. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. J Clin Investig. 2016;126:181–94.
doi: 10.1172/JCI83013
Schweighofer CD, Coombes KR, Barron LL, Diao L, Newman RJ, Ferrajoli A, et al. A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia. PloS One. 2011;6:e28277.
doi: 10.1371/journal.pone.0028277
Bologna C, Buonincontri R, Serra S, Vaisitti T, Audrito V, Brusa D, et al. Slamf-1/CD150 is a signaling receptor expressed by a subset of chronic lymphocytic leukemia patients characterized by a favorable prognosis. Blood. 2012;120:1770.
Tassi I, Colonna M, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cgamma signaling pathways in human NK cells. J Immunol. 2005;175:7996–8002.
doi: 10.4049/jimmunol.175.12.7996
Binsky-Ehrenreich I, Marom A, Sobotta MC, Shvidel L, Berrebi A, Hazan-Halevy I, et al. CD84 is a survival receptor for CLL cells. Oncogene. 2014;33:1006–16.
doi: 10.1038/onc.2013.31
Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123:1810–7.
doi: 10.1182/blood-2013-09-527853
Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, et al. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia. 2011;25:101–9.
doi: 10.1038/leu.2010.240
Pazina T, James AM, MacFarlane AW, Bezman NA, Henning KA, Bee C, et al. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. OncoImmunology. 2017;6:e1339853.
Sanchez-Martinez D, Lanuza PM, Gomez N, Muntasell A, Cisneros E, Moraru M, et al. Activated allogeneic NK cells preferentially kill poor prognosis B-cell chronic lymphocytic leukemia cells. Front Immunol. 2016;7:454.
doi: 10.3389/fimmu.2016.00454